Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Stirling Products has received ethics approval on an accelerated basis for its multicenter clinical study of ImmunoXel in seasonal flu. Reaching this milestone brings the Australia-based healthcare company a step closer to conducting an important confirmation trial of the effectiveness of ImmunoXel in treating respiratory infections.
Subscribe to our email newsletter
Stirling was contracted for this clinical trial in late January 2010 and patient recruitment has already commenced and will continue through March 2010.
The study will be conducted in multiple medical centres near Luhansk, Ukraine and involves over a dozen clinicians, including specialists in acute respiratory disease. The benefits of this multi-centre trial include a faster recruitment rate, wider range of population samples, and multiple clinical observers, all such factors supporting a generalized and reliable outcome.
Stirling will provide further advice as this and other clinical trials in Europe and Africa progress during 2010.